This press release reports that over the 12 months of their Expanded Access Program enrolling ten patients, the majority of patients with pulmonary arterial hypertension who completed treatment with drug candidate CS1 maintained or improved their functional and biomarker status, and that CS1 showed a favourable safety and tolerability profile. A Phase IIb trial for CS1 begins this summer. Read the Cereno Scientific press release

Clinical trials for sotatercept didn't include children, so any pediatric use is off-label. This study, conducted at one children's hospital in San Diego, evaluated sotatercept in 7 pediatric patients with pulmonary arterial hypertension who were already on triple therapy. A majority of patients had favourable hemodynamics trends, supporting the need for official pediatric studies. Read the Pediatric Cardiology article

A 9-participant phase 1 clinical trial used a patch to deliver a prodrug of treprostinil (a prodrug is something that is metabolized into the drug in question inside the body). Each participant wore a patch for 24 hours. The researchers found that treprostinil levels were steady, that different patch sizes could probably be used to deliver different doses, and that it was generally safe and well-tolerated. The company plans to continue clinical development. Read the press release